TY - JOUR
T1 - The role of igf/igf-1r signaling in hepatocellular carcinomas
T2 - Stemness-related properties and drug resistance
AU - Ngo, Mai Huong Thi
AU - Jeng, Han Yin
AU - Kuo, Yung Che
AU - Nanda, Josephine Diony
AU - Brahmadhi, Ageng
AU - Ling, Thai Yen
AU - Chang, Te Sheng
AU - Huang, Yen Hua
N1 - Funding Information:
Funding: This study is supported by research grants from Ministry of Science and Technology, Taiwan (Grant numbers: MOST105–2628-B-038-008-MY3, MOST106–3114-B-038-001, MOST107–2321-B-038-002, MOST107–2314-B-038-057, MOST107–2314-B-038-061, MOST108-2314-B-038-006, MOST108–2321-B-038-003, MOST 109-2314-B-038-135, MOST 109-2321-B-038-003, MOST 109-2320-B-002-068, and MOST 109-2314-B-182-025).
Funding Information:
Acknowledgments: We gratefully acknowledge the academic and science graphic illustration service provided by the Office of Research and Development at Taipei Medical University. We also gratefully acknowledge the English editing service from Anita Infante.
Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/2/2
Y1 - 2021/2/2
N2 - Insulin-like Growth Factor (IGF)/IGF-1 Receptor (IGF-1R) signaling is known to regulate stem cell pluripotency and differentiation to trigger cell proliferation, organ development, and tissue regeneration during embryonic development. Unbalanced IGF/IGF-1R signaling can promote cancer cell proliferation and activate cancer reprogramming in tumor tissues, especially in the liver. Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death, with a high incidence and mortality rate in Asia. Most patients with advanced HCC develop tyrosine kinase inhibitor (TKI)-refractoriness after receiving TKI treatment. Dysregulation of IGF/IGF-1R signaling in HCC may activate expression of cancer stemness that leads to TKI refractoriness and tumor recurrence. In this review, we summarize the evidence for dysregulated IGF/IGF-1R signaling especially in hepatitis B virus (HBV)-associated HCC. The regulation of cancer stemness expression and drug resistance will be highlighted. Current clinical treatments and potential therapies targeting IGF/IGF-1R signaling for the treatment of HCC will be discussed.
AB - Insulin-like Growth Factor (IGF)/IGF-1 Receptor (IGF-1R) signaling is known to regulate stem cell pluripotency and differentiation to trigger cell proliferation, organ development, and tissue regeneration during embryonic development. Unbalanced IGF/IGF-1R signaling can promote cancer cell proliferation and activate cancer reprogramming in tumor tissues, especially in the liver. Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death, with a high incidence and mortality rate in Asia. Most patients with advanced HCC develop tyrosine kinase inhibitor (TKI)-refractoriness after receiving TKI treatment. Dysregulation of IGF/IGF-1R signaling in HCC may activate expression of cancer stemness that leads to TKI refractoriness and tumor recurrence. In this review, we summarize the evidence for dysregulated IGF/IGF-1R signaling especially in hepatitis B virus (HBV)-associated HCC. The regulation of cancer stemness expression and drug resistance will be highlighted. Current clinical treatments and potential therapies targeting IGF/IGF-1R signaling for the treatment of HCC will be discussed.
KW - Cancer stemness
KW - IGFs inhibitor
KW - Insulin-like growth factor
KW - Liver cancer
KW - Targeting drug resistance
UR - http://www.scopus.com/inward/record.url?scp=85101003785&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85101003785&partnerID=8YFLogxK
U2 - 10.3390/ijms22041931
DO - 10.3390/ijms22041931
M3 - Review article
AN - SCOPUS:85101003785
SN - 1661-6596
VL - 22
SP - 1
EP - 34
JO - International journal of molecular sciences
JF - International journal of molecular sciences
IS - 4
M1 - 1931
ER -
